

Troglitazone

Troglitazone is a synthetic antidiabetic and anti-inflammatory drug previously prescribed to patients with type 2 diabetes mellitus, but was withdrawn from the market in 2000 due to toxicity issues. Selective agonist of the peroxisome proliferator-activated receptor-γ (PPARγ, EC50=555nM) with no activity for PPARα or PPARδ.

Materials Provided

Catalog Number: 92-1138

Quantity Supplied: 1 vial(s), 5 mg per vial

Description

DiscoverX control ligands have been functionally tested and validated for optimal use with all cell line targets and Assay Ready kits.

Product Information

Molecular Weight: 441.54 g/mol

Source: Synthetic

Purity: ≥ 98% by HPLC

Endotoxin Level: N/A
Formulation: N/A

Storage: ≤ -20°C Please avoid multiple freeze/thaw cycles.

Reagent Preparation

To avoid condensation, equilibrate the vial to ambient temperature before opening.

Stock Concentration:10 mMReconstitution Volume:1.132 mLReconstitution Solvent:DMSO

92-1138 Troglitazone 1

Generated on : June 14, 2022



For Research Use Only

Ordering: +1.510.979.1415 option 4 or e-mail CustomerServiceDRX@eurofins.com Technical support: +1.510.979.1415 option 5 or e-mail DRX_SupportUS@eurofinsUS.com General product information: www.discoverx.com

92-1138 Troglitazone

Generated on : June 14, 2022